Sutro Biopharma (STRO)
Sutro Biopharma, Inc. is a biotechnology company focused on oncology. The company is developing antibody-drug conjugate programs using its cell-free protein synthesis and site-specific conjugation platforms, including XpressCF and XpressCF+. Its pipeline includes STRO-004, which is being studied for solid tumors that express tissue factor, and STRO-003, an ADC aimed at ROR1-related cancers in both solid and blood malignancies. Sutro Biopharma is also advancing VAX-24 and VAX-31, pneumococcal vaccine candidates in late-stage clinical development. In addition to its internal programs, the company has collaboration and license agreements with Vaxcyte, Tasly Biopharmaceuticals, Ipsen, and Astellas Pharma. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma trades on the NASDAQ under the symbol STRO.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-STRO
|
$26.36
|
15.9% Upside
|
Fair
|
$47.75
|
109.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-2.5x
|
-5.7x
|
3.8x
|
374.3 M
|
193.1 M
|
3.5%
|
62.2%
|
-5.2
|
—
|
99.0%
|
